About DentaBiotic™

DentaBiotic™ is a completely new approach to managing oral health with probiotics, with specific focus on gingivitis. This unique formulation is clinically documented to improve oral conditions present with gingivitis.

  • Lactobacillus rhamnosus

  • Lactobacillus curvatus

    The probiotic strains have been carefully selected based on screening of the effect on pathogens associated with gingivitis and periodontitis. DentaBiotic™ is manufactured in cGMP FDA Approved Facility.

    > ORDER NOW

    > Watch our new DentaBiotic commercial

    Gingivitis and periodontitis
    Gingivitis is an inflammatory condition in the tissue surrounding the teeth caused by a buildup of dental plaque (biofilm). Pathogenic bacteria accumulate on the biofilm and damage the gums, resulting in inflammation, known as gingivitis.

    The typical signs of this early stage gum disease are red, swollen gums that bleed easily (Duran-Pinedo 2015). At this stage, the disease is reversible and can usually be eliminated by good dental hygiene. In a clinical trial with DentaBiotic™, significant reduction in the markers of gingivitis was shown.

    Left untreated, gingivitis can lead to the more serious and irreversible periodontitis, which destroys the gums and bone that support the teeth, leading to loose teeth that have to be removed.



    During the buildup of dental plaque, the bacterial composition in the oral cavity changes and the number of bacteria causing gum disease increases. Recent studies have found that the primary bacteria causing gum diseases include Porphorymonas (P.) gingivalis, Aggregatibacter (A.) actinomycetemcomitans, as well as Prevotella intermedia and Fusobacterium nucleatum (How 2016).

    In addition to uncomfortable manifestation in the mouth, gingivitis and periodontitis affect the immune system, as a result of pathogenic bacteria inducing inflammation in the gum tissue (Silva 2015).

    Currently, periodontal disease is treated by physical removal of biofilm, antibiotics and potential surgical removal of dead or damaged tissue. Antimicrobial oral rinses may also be recommended, when combined with other treatments (Laudenbach 2014). However, antimicrobial, oral rinses have side-effects, such as staining of teeth and changes in taste sensation, which highlight the need for new products to support oral health.

    Probiotics
    Probiotic bacteria are defined by FAO/WHO in 2001 as:

    "Live microorganisms which when administered in adequate amounts confer a health benefit on the host"

    For decades, probiotics have been used to improve gut health by maintaining or restoring the microbiota in the intestines. It is now also recognized that a unique microbiota thrives in the mouth, which can equally be maintained or restored with probiotics - A natural way of maintaining oral health.

    The mode of action of probiotics in the mouth is expected to involve both local and systemic interactions; the probiotic strain competes with pathogens for nutrients and binding sites, it produces antimicrobial substances and modulates the mucosal immune system through cytokine regulation, which is visualized in fig. 2 below (Devine 2009; Stamatova 2009).



    Probiotics for oral health care
    A healthy mouth is not a mouth that lacks bacteria but a mouth with a healthy, natural balance of many different bacteria. Administration of probiotics is a new approach to managing oral health by restoring and maintaining a natural and healthy microbiota in the oral cavity.

    Periodontal diseases
    The first studies of the use of probiotics for enhancing oral health were for the treatment of periodontal inflammation (Haukioja 2010). Clinical parameters measured included: plaque index, bleeding index of the gums, immunological and biomolecular markers (Bizzini 2012; Teughels 2011). Evidence of a beneficial effect of probiotics on periodontal diseases is increasing and it was recently concluded in a meta-analysis, that there is in fact evidence for recommending probiotics as a supportive measure in the management of periodontal diseases (Gruner 2016).

    In accordance with above mentioned parameters, the ability of the DentaBiotic™ strains to inhibit growth of a range of oral pathogens associated with periodontal diseases was tested in vitro. Based on this screening, a unique combination of two proprietary lactobacilli was selected for a human clinical trial at the University of Copenhagen.

    The strains selected for DentaBiotic™ have shown a strong capability of inhibiting growth of oral pathogens compared to other probiotic candidates. In a common in vitro method, the two DentaBiotic™ strains showed complete inhibition of F. nucleatum and A. actinomycetemcomitans compared to 6 other probiotic candidates tested, even at a very low number of bacteria used in the experiment.

    Furthermore, the DentaBiotic™ strains were tested for their immunomodulatory properties. Due to the inflammatory changes taking place in the development of gingivitis, probiotics should induce an anti- inflammatory response in order to alleviate the gingival inflammation.

    Both strains have shown significant anti-inflammatory properties, especially on the interaction with dendritic cells. The interleukin-10 (IL-10) and interleukin-12 (IL-
    12) ratio, a predictor of probiotic anti-inflammatory properties, was shown to be high compared to other probiotic strains tested (Foligne 2007).

    Based on results from the in vitro study, DentaBiotic™ strains were selected for a human clinical trial, investigating their effect on gingivitis. The study was done in collaboration with the Department of Odontology at University of Copenhagen. Forty-five adult participants with moderate gingival inflammation were enrolled in the study, and the intervention period lasted for 4 weeks.

    Outcomes included a range of immunological markers, as well as plaque index and bleeding on probing. Most importantly, the amount of gingival crevicular fluid (GCF) in the gingival pockets was included as a point of measure, since it is an indicator of the severity of gingivitis.

    The combination of the two Lactobacillus strains significantly reduced the amount of GCF in the gingival pockets compared to placebo (fig. 3), indicating a less severe inflammation of the gums.

    The DentaBiotic™ study was recently completed and analyses of some parameters are still ongoing.


    How to use DentaBiotic™
    DentaBiotic™ is suitable for adults & seniors to use on a daily basis. Recommended dosage is 2 chewable tablets daily. The product is intended as a supplement to daily oral hygiene routines to support oral health. It is not intended to replace the daily flossing and tooth brushing with fluorinated toothpaste.



    Stability
    Based on SciBiotic’s extensive expertise within probiotic strain selection, product formulation and manufacturing, DentaBiotic™ is designed to have a shelf-life of 18 months when stored at max. 77 °F.


    > ORDER NOW



     

     

     

    REFERENCES:
    
Bizzini B., Pizzo G., Scapagnini G., Nuzzo D., Vasto S., 2012. Probiotics and Oral Health. Current Pharmaceutical Design; 18(34); pp. 5522-5531.

    Devine D.A., Marsh P., 2009. Prospects for the development of probiotics and prebiotics for oral applications. Journal of Oral Microbiology (online).

    Duran-Pinedo A.E., Frias-Lopez J., 2015. Beyond microbial community composition: functional activities of the oral microbiome in health and disease. Microbes and Infection; 17(7); pp. 505-516.

    Foligne B., Nutten S., Grangette C., Dennin V., Goudercourt D., Poiret S., Dewulf J., Brassart D., Mercenier A., Pot B., 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology; 13(2); pp. 236-243.

    Gruner D., Paris S., Schwendicke F., 2016. Probiotics for managing caries and periodontitis: Systematic review and meta-analysis. Journal of Dentistry; 48; pp. 16-25.

    Haukioja A., 2010. Probiotics and Oral Health. European Journal of
    Dentistry; 4; pp. 348-355.

    How K.Y., Song K.P., Chan K.G., 2016. Porphyromonas gingivalis: An overview of periodontopathic pathogen below the gum line. Frontiers in Microbiology; 7(53); pp. 1-14.

    Laudenbach J.M., Simon Z., 2014. Common dental and periodontal diseases: Evaluation and management. Medical Clinics of North America; 98(6); pp. 1239-1260.

    Petersen P.E., Ogawa H., 2012. The global burden of periodontal disease: towards integration with chronic disease prevention and control. Periodontology 2000; 60(1); pp. 15-39.

    Rastogi P., Saini H., Dixit J., Singhal R., 2011. Probiotics and oral health. National Journal of Maxillofacial Surgery; 2(1); pp. 6-9.

    Silva N., Abusleme L., Bravo D., Dutzan N., Garcia-Sesnich J., Vernal R., Hernández M., Gamonal J., 2015. Host response mechanisms in periodontal diseases. Journal of Applied Oral Science; 23(3); pp. 329-355.

    Stamatova I., Meurman J.H., 2009. Probiotics: Health benefits in the mouth. American Journal of Dentistry; 22; pp. 329-338.

    Teughels W., Loozen G., Quirynen M., 2011. Do probiotics offer opportunities to manipulate the periodontal oral microbiota? Journal of Clinical Periodontology; 38 (Supplement 11); pp. 159-177.

     

    SaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSave